Boston Bags Assets From GSK and Novartis

03 Oct 2018

The US firm is getting its hands on eight programs from two of the world's leading drug makers, seeing an opportunity in areas such as antibiotics where solutions may be more likely to come from biotech rather than big pharma.

Gold — Boston pans for gold among big pharma portfolios • Source: Shutterstock

Boston Pharmaceuticals Inc. is the latest beneficiary of big pharma companies paring down their R&D portfolios, after getting hold of early-stage assets from GlaxoSmithKline PLC and Novartis AG.

First up, Boston has in-licensed five programs from GSK, which include two Phase II-ready candidates. GSK3352589 is a novel small-molecule...